Latest Breaking News On - Senior biotechnology research analyst - Page 1 : comparemela.com

IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event

/PRNewswire/ IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted.

Yujiros hataGregory renzaAndres ruiz brisenoExchange commissionSenior biotechnology research analystBiosciences incMarkets global healthcareChief executive officerSenior biotechnology researchAnnual reportVice presidentIdeaya biosciences

IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event

/PRNewswire/ IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted.

Gregory renzaYujiros hataPeter lawsonSenior biotechnology research analystBiosciences incExchange commissionEquity research analystMarkets global healthcareChief executive officerSenior biotechnology researchManaging directorEquity researchAnnual reportIdeaya biosciences

DURECT Corporation to Participate in Fireside Chat at the H C Wainwright BioConnect Investor Conference

DURECT Corporation to Participate in Fireside Chat at the H C Wainwright BioConnect Investor Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJames brownHc wainwright bioconnectEd arceSenior biotechnology research analystDrug administrationExchange commissionHc wainwright coInnocoll pharmaceuticals ltdCorporation nasdaqInnocoll pharmaceuticalsManaging directorBioconnect investor conferenceFast trackPrivate securities litigation reform actNew drug application

DURECT Corporation to Participate in Fireside Chat at the H C Wainwright BioConnect Investor Conference

/PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed.

United statesHc wainwright bioconnectEd arceJames brownInnocoll pharmaceuticals ltdDrug administrationSenior biotechnology research analystInnocoll pharmaceuticalsCorporation nasdaqExchange commissionHc wainwright coManaging directorBioconnect investor conferenceFast trackPrivate securities litigation reform actNew drug application

BioLineRx (BLRX) and Dare Biosciences (DARE), NanoCap Biotech Companies with Phase III Trials Completed and Enough Capital to Launch Products

Nanocap biotech companies with enough capital to launch a new product are a sweet spot for investors in the current market.

United statesJohn vandermostenKumaraguru rajaBiotechnology research at noble life science partnersNanocap biotech companiesCiti researchDrug administrationSenior biotechnology research analystDare biosciencesEnough capitalFederal drugWall street transcriptSenior biotech analystBrookline capital marketsBrookline capitalVice president